As to the opinion of veterinarians, we’ve collected some here:
While no one has the answer for this quite yet, there are several working theories. Scientists at Colorado State University are one of the first groups to formally observe animal reactions to CBD, and their preliminary research suggests CBD interacts with the Endocannabinoid System (“ ECS” ). RJ Silver, the Chief Medical Officer of RxVitamins, writes that the ECS can be found in all mammals, and helps in balancing the immune system, nervous system, and other physiological processes including:
Yes — when used properly. In 2018, Congress removed hemp from the Controlled Substances Act. That means hemp-derived CBD can be legally produced. Further, the Food and Drug Administration (“ FDA ”), which regulates pet food and animal health product, has not objected to the use of CBD in cosmetics and pet topicals. The FDA has, however, clearly prohibited CBD in pet foods and products making medical claims. Some states have additional restrictions on the use and sale of CBD products.
How does CBD work?
A review of existing evidence “suggest[s] that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, [and] sleep disorders;” but the development of CBD-based drugs “requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and safety.”
CBD Isn’t Pot
Topical application “avoids the first-pass metabolism effect that is associated with the oral route and thus improves drug bioavailability.” It is “potentially ideal for localized symptoms, such as those found in dermatological conditions and arthritis.” [ 3 ]
The Company looks forward to further communicating new CBD and other wellness products to improve revenue from Canadian distribution as well as act as proof of concept for international distribution and large pharmaceutical and natural health product contract manufacturing services enabled by the Company’s unique GMP Drug Establishment and Natural Health Product manufacturing licenses.
BARRIE, Ontario, Dec. 22, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has been awarded best CBD brand of the year by Kind Magazine.
According to the Ontario Cannabis Store, Canada’s largest cannabis distributor, in the most recent quarter, CBD-dominant products were the second-fastest selling category, 135 times faster than the slowest selling products. This trend is replicated across the country and provides MediPharm Labs with near term revenue improvement opportunity. The average direct margin on MediPharm CBD oil SKUs is healthy making the expansion of these sales beneficial to positive gross margin.
Barrie, Ontario, CANADA
“MediPharm Labs is honoured to be selected as CBD Brand of the Year. The MediPharm CBD SKUs lead our wellness line of products which are produced to a pharmaceutical quality standard in a GMP licensed facility,” said Bryan Howcroft, CEO, MediPharm Labs. “The award being voted by front line staff of cannabis retailers is a testament to our pharma-quality brand fulfilling wellness consumers’ needs.”
Kind Magazine is published across Canada and distributed in cannabis retail stores. The Kind Awards were determined by a panel of 235 frontline cannabis retail staff. MediPharm Labs has built a reputation for pharma-quality CBD, THC, and CBN oils, which consumers seek for wellness solutions. The advanced quality manufacturing process of MediPharm Labs was also featured on national television on CBC Marketplace as producers highlighted the pitfalls of the CBD black market and the advantages of licensed quality manufactures. The episode, The Truth About CBD, can be viewed online.
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.